Form 4: Cingulate Inc. Executive Matthew Brams Acquires Stock Options

EVP and Chief Medical Officer of Cingulate Inc., Matthew Brams, reports the acquisition of stock options.

Summary

• On March 29, 2024, Matthew Brams, EVP and Chief Medical Officer of Cingulate Inc., acquired 1,000 stock options at an exercise price of $1.1.
• The options, representing the right to buy 1,000 shares of common stock, were granted pursuant to the terms of Mr. Brams' Employment Agreement, as amended.
• The options are exercisable from March 29, 2024, and expire on March 29, 2034.
• Following the transaction, Mr. Brams directly owns 1,000 derivative securities.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing, so the sentiment is neutral. It simply reports a transaction.

Positives

• The acquisition of stock options by a key executive could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders (officers, directors, or those holding more than 10% of the company's shares) trade in the company's securities. It provides transparency into insider transactions.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the pharmaceutical industry, often used to align management's interests with those of shareholders.
• The terms of the option grant, such as the exercise price and vesting schedule, are generally comparable to those offered by similar companies to their executives.
• Comparing the size of the grant to those of executives at peer companies would provide further context.

Stakeholder Impact

• The acquisition of stock options by an executive could have a minor positive impact on shareholder sentiment, as it may signal confidence in the company's future prospects.

Key Dates

Keywords

stock options, Cingulate Inc., Matthew Brams, executive compensation, Form 4, insider trading